Determining the likelihood of a skin cancer spreading to other parts of the body is a fundamental part of the clinical assessment for non-melanoma skin cancer. While both squamous cell carcinoma and basal cell carcinoma are common in the United Kingdom, they exhibit very different biological behaviours regarding their potential for metastasis. One type is noted for its ability to invade local tissues while remaining confined to the original site, whereas the other carries a more significant risk of travelling to the lymph nodes or internal organs. Understanding these differences allows healthcare professionals to tailor treatment plans and follow-up schedules according to the specific risks associated with each cell type.
What We’ll Discuss in This Article
- The biological differences between squamous and basal cells
- Statistical rates of metastasis for both cancer types
- Clinical features that increase the likelihood of spread
- The role of lymph node checks in squamous cell carcinoma management
- Why basal cell carcinoma is rarely staged for distant spread
- How the location of a tumour impacts the risk of invasion
The biological behaviour of basal cell carcinoma
Basal cell carcinoma is the most common form of skin cancer in Britain and is generally considered a slow-growing and localized condition. It arises from the basal cells in the deepest layer of the epidermis and typically expands over many months or years. The defining characteristic of this cancer is its lack of metastatic potential. The National Health Service states that basal cell carcinoma is a slow growing form of skin cancer that almost never spreads to other parts of the body. Because it remains local, deaths from this type of cancer are extremely rare in the UK.
However, the lack of spread to distant organs does not mean the condition is harmless. If left untreated, a basal cell carcinoma can become locally invasive, meaning it continues to grow deeper into the skin and can eventually destroy nearby structures like cartilage, bone, or nerves. This local destruction is why early treatment is still essential. Clinicians often refer to this aggressive local growth as a rodent ulcer because of its tendency to erode the surrounding tissue. Despite this local aggression, the risk of a basal cell carcinoma spreading to regional lymph nodes or distant sites is estimated to be significantly lower than 0.1 per cent.
The metastatic potential of squamous cell carcinoma
Squamous cell carcinoma presents a different clinical challenge because it carries a notable risk of spreading beyond the primary skin site. This cancer originates in the squamous cells of the outer layers of the skin and can grow more rapidly than basal cell tumours. Guidance from the National Institute for Health and Care Excellence highlights that squamous cell carcinoma is associated with a risk of metastasis to lymph nodes and other organs, particularly when high risk features are present. For the majority of patients, the risk of spread is low, but it is much higher than that of basal cell carcinoma.
General clinical data indicates that approximately two to five per cent of squamous cell carcinomas will eventually metastasise. The cancer most frequently travels through the lymphatic system to the nearest group of lymph nodes, such as those in the neck, armpit, or groin. If the cancer is not identified at this stage, it can theoretically spread further to internal organs like the lungs or liver. Because of this risk, squamous cell carcinoma requires a more intensive approach to staging and follow-up than basal cell carcinoma to ensure any spread is identified and managed promptly.
Comparing growth rates and spread
The speed at which a skin cancer grows often correlates with its likelihood of spreading. Squamous cell carcinoma tends to evolve over weeks or months, whereas basal cell carcinoma may remain unchanged for years. This rapid multiplication of squamous cells increases the probability that some cells will break away and enter the lymphatic or blood systems. While a basal cell carcinoma might take a decade to cause significant local damage, a squamous cell carcinoma can become deeply invasive and potentially life-threatening in a much shorter timeframe if it is not addressed.
This difference in growth speed also influences how patients perceive their symptoms. A basal cell carcinoma is often a quiet growth that remains painless for a long time. In contrast, a squamous cell carcinoma is more likely to be tender or painful, which is a sign of local inflammation and rapid expansion. These sensory warnings are helpful clinical indicators that a lesion may have more aggressive potential and requires urgent investigation by a dermatologist.
Factors that increase the risk of SCC spread
While the general risk of spread for squamous cell carcinoma is around five per cent, certain tumours are classified as high-risk because they have a much higher statistical chance of metastasis. Clinicians use several criteria to identify these cases during the diagnostic process. If a tumour is larger than two centimetres in diameter or has grown more than six millimetres deep into the skin, the risk of spread increases significantly. The location of the cancer is also a vital factor, with tumours on the ears or the lips having a higher potential for reaching the lymph nodes.
Other features that raise the level of concern include the appearance of the cells under a microscope. If a pathologist identifies the cancer as being poorly differentiated, it means the cells look very abnormal and are likely to behave aggressively. Perineural invasion, where cancer cells grow along the paths of local nerves, is another high-risk marker. In patients with weakened immune systems, such as organ transplant recipients, the risk of spread can be even higher, necessitating more frequent clinical reviews and more extensive surgical treatments.
Clinical management and lymph node monitoring
Because of the differing risks of spread, the NHS manages these two cancers with distinct clinical pathways. For a basal cell carcinoma, the focus is almost entirely on the local removal of the tumour. Staging scans or lymph node examinations are rarely necessary unless the tumour is exceptionally large or has been present for a very long time. Once the local site is clear, the patient is often discharged with advice on how to monitor for new spots in the future.
The management of squamous cell carcinoma involves a broader assessment. For high-risk cases, a specialist will regularly feel the regional lymph nodes to check for any firmness or swelling. They may also order an ultrasound scan or a biopsy of a suspicious gland to ensure the cancer has not travelled. This increased level of surveillance is the standard of care in the UK for squamous cell carcinoma, as identifying lymphatic spread at an early stage allows for more successful treatment with surgery or radiotherapy.
Impact on long-term surveillance
The higher risk of spread in squamous cell carcinoma means that follow-up appointments are more structured and frequent than for basal cell carcinoma. A patient who has had a high-risk squamous cell carcinoma may be seen by a specialist every few months for several years to monitor the surgical site and the nearby glands. This level of professional oversight provides a safety net that is not typically required for basal cell tumours.
For both types of cancer, having one lesion significantly increases the risk of developing another primary skin cancer in the future. This is because the cumulative sun damage that caused the first cancer is usually present across a wider area of the skin. Therefore, regardless of whether the first diagnosis was a basal cell or squamous cell carcinoma, lifelong self-examination and diligent sun protection remain essential habits for protecting the health of the skin.
Conclusion
Squamous cell carcinoma carries a notably higher risk of spreading to other parts of the body compared with basal cell carcinoma, which almost never metastasises. While the risk for squamous cell tumours is generally around five per cent, it increases with factors like larger size, deep invasion, and location on the ear or lip. Understanding these differences is essential for ensuring that each type of skin cancer receives the correct level of clinical monitoring and treatment within the UK healthcare system. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Is a basal cell carcinoma ever life-threatening?
It is extremely rare for a basal cell carcinoma to be fatal because it almost never spreads to internal organs, though it can cause significant local damage if left untreated.
Why does SCC spread more often than BCC?
The squamous cells are biologically more aggressive and can multiply more rapidly, making it easier for them to invade blood vessels or the lymphatic system.
How can I tell if my skin cancer has spread?
A common sign of spread is a firm, painless lump in the nearby lymph nodes, such as in the neck or armpit, which does not go away.
What is the metastatic rate for BCC?
The rate of metastasis for basal cell carcinoma is estimated to be lower than 0.1 per cent of all cases, making it one of the least likely cancers to spread.
Are there scans to check for skin cancer spread?
Yes, for high-risk squamous cell carcinoma, clinicians may use ultrasound, CT, or MRI scans to check the lymph nodes and internal organs.
Does a high-risk location always mean the cancer will spread?
No, it simply means there is a higher statistical probability, so the medical team will monitor you more closely to catch any changes early.
Is spread to the lymph nodes curable?
Yes, even if a squamous cell carcinoma reaches the lymph nodes, it can often still be successfully treated with a combination of surgery and radiotherapy.
Authority Snapshot (E-E-A-T)
This article is designed to provide clear and factual information regarding skin health for the general public. The content is written by the Medical Content Team and has been reviewed by Dr. Stefan Petrov. He is a UK-trained physician with an MBBS and postgraduate certifications including Basic Life Support (BLS), Advanced Cardiac Life Support (ACLS), and the UK Medical Licensing Assessment (PLAB 1 & 2). He has hands-on experience in general medicine, surgery, anaesthesia, ophthalmology, and emergency care. Dr. Petrov has worked in both hospital wards and intensive care units, performing diagnostic and therapeutic procedures, and has contributed to medical education by creating patient-focused health content and teaching clinical skills to junior doctors.
